This pathophysiology diagram illustrates the molecular mechanism by which curcumin nanoparticles (CUR-NPs) inhibit asthma-related changes in airway smooth muscle cells (ASMCs). The diagram shows a vertical signaling cascade starting with CUR-NPs exerting an inhibitory effect (indicated by a T-bar arrow) on Transforming Growth Factor-beta 1 (TGF-̢1). This suppresses the downstream signaling pathway consisting of phosphorylated Signal Transducer and Activator of Transcription 3 (p-STAT3) and Connective Tissue Growth Factor (CTGF). The activation of CTGF is linked via branching arrows to three key pathological processes in ASMCs: cell proliferation (depicted as a dense cluster of nucleated cells), cell migration (shown as cells passing through a basement membrane), and inflammation (represented by small red circular markers labeled with 'TGF-̢1 ↑'). The flow indicates that by targeting the TGF-̢1/p-STAT3/CTGF axis, CUR-NPs can mitigate airway remodeling and inflammatory infiltration in conditions like asthma. This pedagogical visual is designed for intermediate to advanced medical education regarding pharmacology and respiratory pathophysiology.

This pathophysiology diagram illustrates the mechanisms by which Type 1 inflammation in asthma may destabilize respiratory control, potentially contributing to obstructive sleep apnea (OSA). A sagittal profile of a human head and neck highlights the brain, brainstem, and central nervous system as the primary regulatory sites. Three key neural-immune pathways are detailed via callouts: 1) Microglial cytokine production, depicting an activated microglial cell with branching processes releasing signaling molecules; 2) Cytokine transport across the blood-brain barrier (BBB), shown as molecules moving from a peripheral blood vessel into the central nervous system parenchyma; and 3) Inflammatory neurotransmitters via the Vagus nerve, represented by an ascending neural pathway from the lungs/airways carrying afferent signals. Additional elements include 'Sputum neutrophils' indicating airway inflammation and 'LTF' (Long-Term Facilitation), representing a compensatory mechanism for respiratory stability that becomes compromised. The diagram serves as an educational tool for pulmonologists and neurologists to understand the neuro-inflammatory cross-talk involving central chemoreceptors and peripheral lung injury.

This pathophysiology diagram illustrates extracellular vesicle (EV)-mediated signaling within the lung microenvironment during allergic asthma. The schematic shows how allergen exposure triggers the Airway Epithelium to release EVs containing Leukotriene LTB4, mitochondria, and miRNAs (miR-34a, miR-92b, miR-210) to stimulate Dendritic Cells (DCs). These DCs, alongside B cell-derived EVs (carrying Ag-MHC II, CD40, CD80, CD86, and HSP70), promote the activation of naïve T cells (Th0). The Th0 cells differentiate into Th2, Th17, and Regulatory T cells (Tregs). A key regulatory pathway is shown where Treg-derived EVs inhibit Th2 and Th17 responses (indicated by '-' symbols). Th2 and Th17 cells release EVs that activate effector cells, including Mast cells, Eosinophils, and Neutrophils. The resulting phenotypic changes culminate in increased lung inflammation, airway hyperresponsiveness (AHR), and airway remodeling. The diagram utilizes arrows to denote communication flow, with (+) indicating promotion/maturation and (-) indicating inhibition, highlighting the complex immune crosstalk in asthma pathogenesis.

This medical illustration depicts the polarization and functional diversity of M1 and M2 macrophage phenotypes in the context of asthma pathogenesis. The diagram is divided into two main sections. On the left, an M1 macrophage (classically activated) is shown responding to LPS and IFN-γ. It releases proinflammatory mediators including TNF-α, IL-1β, IL-6, IL-8, IL-18, CXCL10, and CCL5, contributing to oxidative stress and airway damage. On the right, the M2 macrophage (alternatively activated) is shown as a central hub differentiating into four distinct subtypes: M2a (activated by IL-4/IL-13), M2b (by LPS/IL-1β), M2c (by IL-10/TGF-β), and M2d (by IL-6/adenosines). Each M2 subtype is associated with specific effector molecules and clinical roles: M2a is linked to wound healing and tissue remodeling; M2b to immune regulation; M2c to inflammation resolution and fibrosis; and M2d has an unknown function in this context. The diagram illustrates the complex immunological balance between pro-inflammatory M1 responses and the immunomodulatory or tissue-repairing roles of M2 subtypes in asthmatic airway disease.